Unlike a vaccine, the immunization provides ... 90% effective at preventing hospitalization for RSV, and 89% effective at preventing all types of doctor visits for the virus.

In this piece, we include reporting tips, how vaccine side effects are tracked in the U.S., and what research shows about the ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...

Bagdasarian also recommends ensuring kids take in a lot of fluids and said over the counter medicines like Tylenol and ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...

High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants. The rollout of 2 major interventions to prevent severe respiratory syncytial virus (RSV ...

Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...

Research by Public Health Scotland (PHS), published in The Lancet Infectious Diseases Journal, shows uptake of the vaccine resulted in a 62% reduction in RSV-related hospitalisations among the ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The hospital has seen over 200 RSV admissions this winter, but a new preventative measure offers hope. "They came out with a vaccine for babies six months and younger, so that can definitely help ...